Skip to main content
. 2021 Jul 12;95(15):e02425-20. doi: 10.1128/JVI.02425-20

TABLE 1.

ART-suppressed participant clinical dataf

Participant IDe Sexa Ageb (yrs) Ethnicity ART regimen Duration of undetectable viral load (mo) Viral load (copies/ml) Estimated time between infectionc and ART initiation (mo)
OM5011d M 46 White 3TC/ABC/DTG 133 <50 38
OM5267 M 28 White 3TC/ABC/Ral 91 <50 4
OM5148d M 48 White 3TC/ABC/NVP 149 <50 57
OM5365d M 58 White 3TC/ABC/DRV/RTV/ETR/MVC/ 114 <50 18
WWH-B008d M 64 Black ETR/TAF/FTC/DRV/RTV ∼47 <50 ∼60
WWH-B011 M 55 White TAF/FTC/RPV ∼76 <50 ∼264
a

M, male.

b

Age indicates participants’ age at time of leukapheresis.

c

Infection time refers to the HIV-positive detection date.

d

Participants used for primary cell of latency model generation and HIV-positive donor spiked HIVE assays.

e

All 6 participants shown in the table were used for ex vivo HIVE assays.

f

Clinical data of HIV-negative participants, which were used for latency model generation and HIV-negative donor spiked HIVE assays, are not available.